Acetaminophen and Ibuprofen With and Without Magnesium and Primary Migraine in Childhood
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01756209|
Recruitment Status : Completed
First Posted : December 25, 2012
Last Update Posted : December 25, 2012
Aim: The purpose of this study was to evaluate both the effects of ibuprofen and/or acetaminophen for the acute treatment of primary migraine in children in or out prophylactic treatment with magnesium.
Methods: The study had been approved by the Researchers Ethics Committee of the "Pugliese-Ciaccio" Hospital (protocol number 720/2010; EUDRACT NUMBER 2012-005737-36) and the children ranging from the ages of 5 to 18 years with at least four attack/month of primary migraine were enrolled. A Visual Analogical Scale was used to evaluate pain intensity at the moment of admission to the study (start of the study) and every month up to 18 months later (end of the study).
|Condition or disease|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||160 participants|
|Target Follow-Up Duration:||18 Months|
|Official Title:||The Effects of Acetaminophen and Ibuprofen With and Without Magnesium in the Treatment of Primary Migraine in Childhood|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||February 2012|
|Actual Study Completion Date :||February 2012|
- pain-relief [ Time Frame: 3 and 18 months ]The primary endpoint was when pain-relief took place and pain intensity differences from baseline (0 hour) to 3 hours after drug treatment. This measurement was defined as the AUC for the sum of the 2 measurements (pain relief and pain intensity difference) at each time point from 0 to 3 hours.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01756209
|Pugliese Ciaccio Hospital|
|Catanzaro, Italy, 88100|